Study of SU011248 in Patients with Neuroendocrine Tumors

The primary objective of the study is to determine the efficacy and safety of SU011248 as a treatment for patients with advanced unresectable neuroendocrine tumor; however, CURRENTLY ONLY RECRUITING FOR PATIENTS SPECIFICALLY WITH PANCREATIC ISLET CELL TUMORS.

Official Title

Phase II Study of SU011248 in Patients with Neuroendocrine Tumors; however, CURRENTLY ONLY RECRUITING FOR PATIENTS SPECIFICALLY WITH PANCREATIC ISLET CELL TUMORS

Conditions

Neuroendocrine TumorCarcinoid Tumor

Study Type

Interventional

Study Design

Treatment, Safety/Efficacy Study

Further Details

Study Start

March 2003

Eligibility & Criteria

Inclusion Criteria:- Eligible patient must be at least 18 years of age with a diagnosis of carcinoid (no longer recruiting) or pancreatic islet cell tumor. The disease must not be amenable to surgery, radiation, or combined modality therapy with curative intent – Any side effects from prior therapy must have subsided – Blood and urine tests must show adequate bone marrow, liver, and kidney function Exclusion Criteria:The presence of any of the following will exclude a patient from study participation: – diagnosis of small-cell carcinoma – pheochromocytoma/paraganglioma – Merkel cell carcinoma – known brain or leptomeningeal disease – Cardiovascular diseases or conditions – known HIV or AIDS-related illness – pregancy or breastfeeding – Other specific inclusion/exclusion criteria may apply. In order to determine eligibility, further examination by the investigator is necessary.

Total Enrolment

Contact Details

Call: 1-734-622-7600 ClinicalTrials.gov@Pfizer.com